Tencent has led a series E-plus round for Taimei as part of a capital influx totalling $212m, with SoftBank's SBCVC unit also among the investors.

China-based clinical research software provider Taimei Technology has disclosed RMB1.5bn ($212m) in funding including a $132m series E-plus round led by internet group Tencent, DealStreetAsia reported on Friday citing an announcement on WeChat. The total also includes a series E round led by hedge fund manager Tiger Global Management, some details of which were revealed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.